Literature DB >> 21288079

The search for effective treatment of Clostridium difficile infection.

Herbert L DuPont.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21288079     DOI： 10.1056/NEJMe1013236

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  18 in total

1.  Fidaxomicin: in Clostridium difficile infection.

Authors:  Sean T Duggan
Journal:  Drugs       Date:  2011-12-24       Impact factor: 9.546

2.  Nonantimicrobial drug targets for Clostridium difficile infections.

Authors:  Charles Darkoh; Magdalena Deaton; Herbert L DuPont
Journal:  Future Microbiol       Date:  2017-07-31       Impact factor: 3.165

3.  Predictors and outcomes of readmission for Clostridium difficile in a national sample of medicare beneficiaries.

Authors:  Courtney E Collins; M Didem Ayturk; Fred A Anderson; Heena P Santry
Journal:  J Gastrointest Surg       Date:  2014-11-19       Impact factor: 3.452

Review 4.  Clostridium difficile infection: guideline-based diagnosis and treatment.

Authors:  Christoph Lübbert; Endres John; Lutz von Müller
Journal:  Dtsch Arztebl Int       Date:  2014-10-24       Impact factor: 5.594

Review 5.  The intestinal microbiota and chronic disorders of the gut.

Authors:  Andrew W DuPont; Herbert L DuPont
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-08-16       Impact factor: 46.802

Review 6.  Clostridial toxins: sensing a target in a hostile gut environment.

Authors:  Numan Oezguen; Trevor D Power; Petri Urvil; Hanping Feng; Charalabos Pothoulakis; Jonathan S Stamler; Werner Braun; Tor C Savidge
Journal:  Gut Microbes       Date:  2012-01-01

7.  Derivation and Validation of a Clostridium difficile Infection Recurrence Prediction Rule in a National Cohort of Veterans.

Authors:  Kelly R Reveles; Eric M Mortensen; Jim M Koeller; Kenneth A Lawson; Mary Jo V Pugh; Sarah A Rumbellow; Jacqueline R Argamany; Christopher R Frei
Journal:  Pharmacotherapy       Date:  2018-02-22       Impact factor: 4.705

8.  New Role for FDA-Approved Drugs in Combating Antibiotic-Resistant Bacteria.

Authors:  Jourdan A Andersson; Eric C Fitts; Michelle L Kirtley; Duraisamy Ponnusamy; Alex G Peniche; Sara M Dann; Vladimir L Motin; Sadhana Chauhan; Jason A Rosenzweig; Jian Sha; Ashok K Chopra
Journal:  Antimicrob Agents Chemother       Date:  2016-05-23       Impact factor: 5.191

9.  Colonic immunopathogenesis of Clostridium difficile infections.

Authors:  Charles Darkoh; Bradley P Turnwald; Hoonmo L Koo; Kevin W Garey; Zhi-Dong Jiang; Samuel L Aitken; Herbert L DuPont
Journal:  Clin Vaccine Immunol       Date:  2014-01-29

Review 10.  Fidaxomicin: a review of its use in patients with Clostridium difficile infection.

Authors:  Lesley J Scott
Journal:  Drugs       Date:  2013-10       Impact factor: 9.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.